186 related articles for article (PubMed ID: 23599074)
1. Efficacy and toxicity of peritumoral delivery of nanoconjugated cisplatin in an in vivo murine model of head and neck squamous cell carcinoma.
Cohen SM; Rockefeller N; Mukerji R; Durham D; Forrest ML; Cai S; Cohen MS; Shnayder Y
JAMA Otolaryngol Head Neck Surg; 2013 Apr; 139(4):382-7. PubMed ID: 23599074
[TBL] [Abstract][Full Text] [Related]
2. Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.
Sim MW; Grogan PT; Subramanian C; Bradford CR; Carey TE; Forrest ML; Prince ME; Cohen MS
Laryngoscope; 2016 May; 126(5):E184-90. PubMed ID: 26690734
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo.
Cohen SM; Mukerji R; Cai S; Damjanov I; Forrest ML; Cohen MS
Am J Surg; 2011 Dec; 202(6):646-52; discussion 652-3. PubMed ID: 21982998
[TBL] [Abstract][Full Text] [Related]
4. Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents.
Cohen SM; Mukerji R; Samadi AK; Zhang X; Zhao H; Blagg BS; Cohen MS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3(Suppl 3):S483-90. PubMed ID: 21837531
[TBL] [Abstract][Full Text] [Related]
5. Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model.
Chen FA; Kuriakose MA; Zhou MX; DeLacure MD; Dunn RL
Head Neck; 2003 Jul; 25(7):554-60. PubMed ID: 12808659
[TBL] [Abstract][Full Text] [Related]
6. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
[TBL] [Abstract][Full Text] [Related]
7. A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.
Lin Y; Luo J; Zhu WE; Srivastava M; Schaue D; Elashoff DA; Dubinett SM; Sharma S; Wu B; St John MA
Otolaryngol Head Neck Surg; 2014 Sep; 151(3):447-53. PubMed ID: 24825873
[TBL] [Abstract][Full Text] [Related]
8. Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck.
Cai S; Xie Y; Davies NM; Cohen MS; Forrest ML
Ther Deliv; 2010 Aug; 1(2):237-45. PubMed ID: 21339844
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of a fixed dose of cisplatin with increasing doses of raltitrexed (Tomudex) in the treatment of patients with locally advanced or metastatic squamous cell carcinoma of the head and neck.
ten Bokkel Huinink D; Tesselaar ME; Baatenburg de Jong RJ; Verschuur HP; Keizer HJ
Ann Oncol; 2001 Mar; 12(3):357-63. PubMed ID: 11332149
[TBL] [Abstract][Full Text] [Related]
10. A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model.
Hu D; Lau OD; Wang L; Wang G; Schaue D; Zhu L; Huang M; Lin Y; Dennis M; Abemayor E; Elashoff DA; Dubinett SM; McBride WH; Sharma S; Wu B; St John MA
Arch Otolaryngol Head Neck Surg; 2012 Apr; 138(4):412-7. PubMed ID: 22508626
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
[TBL] [Abstract][Full Text] [Related]
12. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
[TBL] [Abstract][Full Text] [Related]
13. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.
Lee SY; Choi YS; Song IC; Park SG; Keam B; Yang YJ; Song EK; Lee HJ; Cho SH; Shim H; Park KU; Lee KH; Jo DY; Jo IS; Yun HJ;
Medicine (Baltimore); 2018 May; 97(21):e10778. PubMed ID: 29794758
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
15. Polymer delivery of chemotherapy for squamous cell carcinoma of the head and neck.
Shikani AH; Eisele DW; Domb AJ
Arch Otolaryngol Head Neck Surg; 1994 Nov; 120(11):1242-7. PubMed ID: 7917208
[TBL] [Abstract][Full Text] [Related]
16. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
Planting AS; Catimel G; de Mulder PH; de Graeff A; Höppener F; Verweij J; Oster W; Vermorken JB
Ann Oncol; 1999 Jun; 10(6):693-700. PubMed ID: 10442192
[TBL] [Abstract][Full Text] [Related]
17. A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo.
Cohen MS; Cai S; Xie Y; Forrest ML
Am J Surg; 2009 Dec; 198(6):781-6. PubMed ID: 19969129
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
19. In squamous cell head and neck cancer: which platinum, how much and how often?
Nwizu T; Adelstein DJ
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1033-9. PubMed ID: 24998393
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.
Planting AS; de Mulder PH; de Graeff A; Verweij J
Eur J Cancer; 1997 Jan; 33(1):61-5. PubMed ID: 9071901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
